Pharvaris NV (PHVS)

NASD · Healthcare · Biotechnology · Netherlands

Pharvaris NV is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Intrinsic value, DCF valuation, financial health and value investing analysis for the Pharvaris NV stock.

Our verdict on PHVS

Not valued: We cannot value this company yet.

ETFs with the most weight in PHVS

Invesco Nasdaq Biotechnology ETF (IBBQ): 0.2% of the fund
iShares Biotechnology ETF (IBB): 0.1% of the fund
Fidelity Nasdaq Composite Index ETF (ONEQ): 0.0% of the fund

Browse

Stocks in Netherlands

Peers in Biotechnology

All 598 Biotechnology stocks

Cheaper than PHVS in Biotechnology

Arbutus Biopharma Corp (ABUS): undervalued, 79% margin of safety
Lakefront Biotherapeutics NV ADR (LKFT): undervalued, 77% margin of safety
CorMedix Inc (CRMD): undervalued, 74% margin of safety
MeiraGTx Holdings plc (MGTX): undervalued, 73% margin of safety
Bicycle Therapeutics Plc ADR (BCYC): undervalued, 71% margin of safety
Innoviva Inc (INVA): undervalued, 71% margin of safety

134 more in this industry show a wider margin of safety.

Is PHVS undervalued or overvalued?

We do not publish a verdict on PHVS yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of PHVS?

We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.